Furthermore, the KEYNOTE‐18910, 11 and KEYNOTE‐40715 study demonstrated that pembrolizumab in combination with chemotherapy could improve OS versus placebo in combination with chemotherapy in nonsquamous and squamous advanced NSCLC without EGFR or ALK mutations and regardless of PD‐L1 expression, respectively. This evidence concerns the gene EGFR and non-small cell lung carcinoma.